Search results
-
ESMO 2025 – Merck shoots for an ovarian cancer first
ESMO 2025 – Merck shoots for an ovarian cancer first …
- 05/19/2026 - 19:49 -
ESMO 2025 – Lilly overshadows Astra’s folate reveal
ESMO 2025 – Lilly overshadows Astra’s folate reveal …
- 05/19/2026 - 19:49 -
ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast
ESMO 2025 – Datroway and Trodelvy face off in … & OS was co-primary endpoint in Tropion-Breast02. Source: ESMO 2025. Overall survival was a different story, …
- 05/19/2026 - 19:49 -
ESMO 2025 – Tubulis keeps the NaPi2b dream alive
ESMO 2025 – Tubulis keeps the NaPi2b dream alive …
- 05/19/2026 - 19:49 -
ESMO 2025 – domvanalimab flies the flag for TIGIT
ESMO 2025 – domvanalimab flies the flag for TIGIT …
- 05/19/2026 - 19:49 -
ESMO 2025 – Celcuity fights for a share of the breast cancer market
ESMO 2025 – Celcuity fights for a share of the breast …
- 05/19/2026 - 19:49 -
ESMO 2025 – synthetic lethality leaves much to prove
ESMO 2025 – synthetic lethality leaves much to prove …
- 05/19/2026 - 19:49 -
ESMO 2025 – Enhertu’s perioperative Destiny beckons
ESMO 2025 – Enhertu’s perioperative Destiny beckons … syndrome (last 2 outdside AE reporting period). Source: ESMO 2025. As for Destiny-Breast11, this compared … endpoint. THP=paclitaxel, Herceptin & Perjeta. Source: ESMO 2025. Conferences Trial …
- 05/19/2026 - 19:49 -
ESMO 2025 – Roche sticks it to its SERD rivals
ESMO 2025 – Roche sticks it to its SERD rivals …
- 05/19/2026 - 19:49 -
ESMO 2025 – iza-bren’s US backing comes with toxicity
ESMO 2025 – iza-bren’s US backing comes with toxicity …
- 05/19/2026 - 19:49
